Foghorn Therapeutics is changing its plans after ending its partnership with Eli Lilly.

Oct 1, 2026, 12:22 PM ETDealRead the original at Benzinga

Bad for FHTX

Foghorn will stop advancing 2 Lilly-linked programs. Its own EP300 research showed promising animal results, and staff cuts are expected to fund work into 2029.

FHTX · Foghorn Therapeutics Inc.

AI read · Bad for FHTX

The AI's read

Foghorn loses a partner on drug work that will not move into wider testing. That leaves its own research to carry the effort. Its EP300 drug showed promise in animal tests. Staff cuts are expected to keep its research funded into the second half of 2029. But human testing is only planned for 2027, so early lab results do not yet replace the stopped programs.

LLY · Eli Lilly & Co.

AI read · Neutral

The connection

Lilly and Foghorn will stop work on 2 joint drug programs. The report does not say this changes Lilly's wider business outlook.

Get alerts for FHTX

Follow Foghorn Therapeutics Inc. (FHTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for FHTX

Free on the App Store and Google Play, or on the web.